Universal Influenza Vaccines 2022

5-7 September 2022, The Richard Doll Building, University of Oxford, Oxford, UK

  • Increase font size
  • Default font size
  • Decrease font size

Day Three

Provisional Conference Programme | Wednesday 7th September 2022


Moderator: Othmar Engelhardt
(NIBSC, South Mimms, Potters Bar, UK)

‘Phase 3 results of quadrivalent nanoparticle influenza (Nanoflu) with Matrix-M™ adjuvant in adults 65 and older’
Vivek Shinde, Iksung Cho, Lou Fries, Jamie Fiske and Greg Glenn
(Novavax Inc.,Gaithersburg, Maryland, USA)

‘OVX836, a novel universal influenza a vaccine candidate: Short-term results of a phase i clinical trial in humans’
K, Withanage1, P.Van Damme1, A. LeVert2, S. Viviani2, P. Willems2 and F. Nicolas2
(1 University of Antwerp, Belgium; 2 Osivax, Lyon, France)

‘Development of T cell-targeted universal influenza vaccines’
Christopher S. Eickhoff1, Frances E. Terry2, Krystal A. Meza1, Lenny Moise2,3, Anne S. De Groot2,3 and Daniel F. Hoft1,4
(1 Saint Louis University, Division of Infectious Diseases, Allergy and Immunology, Departments of Internal Medicine1 and Molecular Microbiology4, Saint Louis, Missouri, USA; 2 EpiVax, Inc., Providence, Rhode Island, USA; 3 University of Rhode Island; Institute for Immunology and Informatics, Providence, Rhode Island, USA)

'Single-replication intranasal BM2SR vaccine provides cross-lineage protection against influenza B virus'
Pamuk Bilsel1, Mike Moser1, David Marshall1, Yasuko Hatta1 and Sally Sarawar2
(1 FluGen, Inc. Madison, Wisconsin, USA; 2 BRISC, San Diego, California, USA)

Coffee Break & Posters


Panel Discussion:
‘The elusive universal influenza vaccine: The way forward’

Moderator: To Be Confirmed

Lunch Break & Posters Breakdown


Moderator: Sarah Gilbert
(The Jenner Institute, University of Oxford, Oxford, UK)

‘Harnessing the clec9a-targeting strategy to boost the immunogenicity of the universal flu antigen vaccine candidate M2e’
Ranmali Kavishna1, Mireille Lahoud2 and Sylvie Alonso1
(1 Department of Microbiology & Immunology, Yong Loo Lin School of Medicine; and Immunology Programme, Life Sciences Institute, National University of Singapore, Singapore; 2 Department of Biochemistry and Molecular Biology, Monash University, Clayton, Australia)

‘Systemic and respiratory T-cells induced by seasonal H1N1 influenza protect against pandemic H2N2 in ferrets’
K. van de Ven, H. van Dijken, F. de Heij and J. de Jonge
(Centre for Infectious Disease Control (Cib), National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands)

‘Universal vector influenza vaccines: Pre-clinical research’
Igor Krasilnikov1, Ludmila Tzibalova2 and Marina Stukova2
(1 Saint-Petersburg Institute of Vaccines and Sera, FMBA Russia, St.- Petersburg, Russia; 2 Smorodintsev Research Institute of Influenza, St.-Petersburg, Russia)

‘SEC meets TRPS: Automated isolation and high-precision analysis of extracellular vesicles and viruses’
Camille Roesch1, Anoop K. Pal2, Shayne Harrel3, Robert Vogel2 and Murray Broom2
(1 Izon Science Europe Ltd, Lyon, France; 2 Izon Science Ltd, Medford, Massachusetts, USA; 3 Izon Science Ltd, Christchurch, New Zealand)

‘Nano-flow cytometry: A platform for comprehensive virus and extracellular vesicle analysis’
Dimitri Aubert
(NanoFCM, Medicity, Nottingham, UK)

Latebreaker abstracts for oral presentation at UIV 2021 are called for.

Authors interested in submitting latebreaker oral abstracts should submit their abstracts directly to John Herriot at Meetings Management (UIV 2021 Organizers).

Closing date for latebreaker oral/poster submissions is Friday 18th February 2022


UIV 2022 Delegates

Login details will be supplied after you have registered for the event.

UIV 2022 Sponsors

  • The Native Antigen Company
  • DNAvaccine.com
  • Izon Science
  • FluConsult
  • BiondVax
  • NanoFCM
  • Sanofi Pasteur
  • VisMederi
  • Vaxart

UIV 2022 Mailing List

E-mail Address
What is 3+2-1?